Maiwei Bio-U (688062): Innovation Pipeline Steadily Promotes Active Layout of Value Deposits

huaxi securitiesNov 2, 2024 00:00

Financial Report Review U (688062): NECTIN-4 ADC Shows Pancreatic Potential to Rapidly Advance Clinical Registration

國信證券Sep 13, 2024 18:21

Maiwei Biotech (688062): ADC R&D is steadily promoting continuous sales volume

Sep 4, 2024 10:41

Maiwei Biotech (688062): NECTIN-4 ADC has rapid clinical progress and is expected to be approved for marketing in 2025

Sep 1, 2024 00:00

Maiwei Biotech (688062): The whole chain of progressive innovation is about to reap differentiated results

Jul 12, 2024 18:26

Maiwei Bio-U (688062): 9MW2821 debuted at ASCO, successful in innovative research and development

May 29, 2024 00:00

Maiwei Biology (688062): High quality ADC platform company with good clinical data for multiple indications

May 26, 2024 00:00

Guoxin Securities released a research report on April 19 stating that Maiwei Biotech (688062.SH) was rated to increase its holdings. The main reasons for the rating include: 1) rapid growth in product sales; 2) commercialization of core products is progre

Zhitong FinanceApr 19, 2024 18:33

Maiwei Bio-U (688062): NECTIN-4 ADC multi-indication rapid clinical promotion

Apr 19, 2024 16:21

Maiwei Biology (688062): Analogs are entering the harvest period and the development of new drugs is being promoted efficiently

Apr 18, 2024 11:16

Maiwei Biotech (688062): ADC released multiple data and commercialization of similar drugs in China progressed smoothly

Apr 17, 2024 11:11

Huajin Securities released a research report on April 13 stating that Maiwei Biotech (688062.SH) was given a purchase rating. The main reasons for the rating include: 1) Milesu's marketing contribution; 2) the commercialization of biosimilar drugs is prog

Zhitong FinanceApr 13, 2024 22:35

Maiwei Biotech (688062): Commercialization and capacity construction are steadily advancing, and the NECTIN-4 ADC multi-pipeline is progressing positively

Apr 13, 2024 00:00

Maiwei Bio-U (688062): NECTIN4 ADC shows excellent data in multiple cancer types

Apr 12, 2024 16:26

SDIC Securities released a research report on April 10 stating that Maiwei Biotech (688062.SH) was given a purchase rating and the target price was 47.95 yuan. The main reasons for the rating include: 1) NECTIN-4 ADC is worth looking forward to; 2) Long-a

Zhitong FinanceApr 11, 2024 07:25

Maiwei Biotech (688062) First Coverage Report: Core Product NECTIN-4 ADC Global Progress Leading Product Pipeline Collaborative Promotion at Home and Abroad

Mar 21, 2024 07:41

Maiwei Biotech (688062): Differential Innovation Accelerates NECTIN-4 ADC Leading Global Progress

Mar 12, 2024 18:32

Maiwei Biotech (688062): NECTIN-4 ADC, an innovative pharmaceutical company with comprehensive capabilities, leads the way

Feb 1, 2024 07:51

Maiwei Bio-U (688062): NECTIN4ADC launches phase III innovation platform and continues to deliver

Dec 17, 2023 07:22

Maiwei Biotech (688062): BIOPHARMA can be expected to grow, innovation is beginning to shine

Dec 10, 2023 00:00